Clinic
Medstar - Georgetown Medical Center, INC.
Medstar - Georgetown Medical Center, INC. was paid $45.62M by Medicaid between Jan 2018 and Dec 2024, across 328 billing codes. Its largest line is 99283, emergency room visit (moderate) — 9.7% of everything it billed.
33Billing provider infoMEDSTAR - GEORGETOWN MEDICAL CENTER, INC.
WASHINGTON, DC 20007
WASHINGTON, DC 20007
33aNPI1427145176assigned 10/06/2006
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$45.62M
24GClaims775,622
24DCodes billed328
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in District of Columbia
Rank by total paid#2 of 22
Median peer was paid$2.28M
This provider vs. median20×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 106,298 | $3.48M | |
| 2019 | 120,603 | $4.46M | |
| 2020 | 101,882 | $3.74M | |
| 2021 | 133,495 | $6.37M | |
| 2022 | 127,382 | $10.23M | |
| 2023 | 102,347 | $9.45M | |
| 2024incomplete | 83,615 | $7.89M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.7% | 19,043 | 16,788 | $4.43M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.3% | 7,854 | 6,417 | $4.27M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.9% | 19,297 | 7,350 | $3.62M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.5% | 11,992 | 10,902 | $2.97M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.6% | 12,511 | 11,240 | $2.55M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.0% | 11,773 | 9,363 | $2.29M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 4,930 | 4,472 | $1.28M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.5% | 1,728 | 1,561 | $1.16M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.5% | 17,422 | 13,695 | $1.14M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 5,498 | 4,132 | $1.02M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 5,029 | 4,581 | $1.01M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.1% | 12,463 | 4,645 | $976K |
316 more codes
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.1% | 1,230 | $942K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.9% | 2,199 | $864K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.9% | 7,522 | $861K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.9% | 7,470 | $847K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 3,304 | $769K |
| 96415 | 1.3% | 1,757 | $601K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 2,933 | $565K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.2% | 4,743 | $553K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.2% | 2,420 | $541K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.2% | 1,408 | $539K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.2% | 3,169 | $534K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.1% | 2,908 | $514K |
| 29581 | 1.1% | 3,526 | $489K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.0% | 2,186 | $463K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,597 | $442K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 897 | $434K |
| 74183 | <1% | 1,215 | $423K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,257 | $413K |
| G0378 | Hospital observation service, per hour | <1% | 5,703 | $371K |
| 97161 | <1% | 1,496 | $337K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,417 | $330K |
| 97162 | <1% | 1,509 | $326K | |
| 96367 | <1% | 2,129 | $317K | |
| 76642 | <1% | 1,785 | $302K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 289 | $279K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 626 | $276K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,206 | $275K |
| 76830 | Ultrasound, transvaginal | <1% | 2,242 | $241K |
| 97597 | <1% | 1,448 | $204K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 140 | $204K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 995 | $199K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,830 | $196K |
| 80053 | Comprehensive metabolic panel | <1% | 27,185 | $169K |
| 73562 | <1% | 3,609 | $147K | |
| 11043 | <1% | 334 | $144K | |
| 93971 | <1% | 1,278 | $137K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 738 | $125K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,685 | $124K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,688 | $122K |
| 59025 | Fetal non-stress test | <1% | 382 | $120K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,235 | $120K |
| 71250 | <1% | 1,495 | $118K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 91 | $114K |
| 97165 | <1% | 835 | $114K | |
| 73564 | <1% | 939 | $89K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 570 | $81K |
| 73502 | <1% | 2,004 | $79K | |
| 72100 | <1% | 1,882 | $78K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,769 | $77K |
| J0485 | Injection, belatacept, 1 mg | <1% | 128 | $75K |
| 93970 | <1% | 428 | $73K | |
| 72141 | <1% | 368 | $71K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26,358 | $71K |
| 73030 | <1% | 2,206 | $70K | |
| 86832 | <1% | 1,083 | $64K | |
| 72040 | <1% | 1,416 | $63K | |
| 93976 | <1% | 627 | $59K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 434 | $58K |
| 87497 | <1% | 3,937 | $52K | |
| 93975 | <1% | 253 | $51K | |
| 77062 | <1% | 770 | $51K | |
| 73630 | <1% | 3,112 | $50K | |
| 97163 | <1% | 280 | $49K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,803 | $48K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,886 | $48K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,291 | $47K |
| 70496 | <1% | 120 | $46K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 52,745 | $46K |
| 86833 | <1% | 1,085 | $40K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 222 | $39K |
| 97116 | <1% | 516 | $38K | |
| 76536 | <1% | 253 | $38K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 259 | $37K |
| 72197 | <1% | 56 | $34K | |
| 80197 | <1% | 5,617 | $33K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 625 | $31K |
| 76775 | <1% | 256 | $31K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,436 | $30K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 20 | $30K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,567 | $30K |
| 73610 | <1% | 2,525 | $27K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 38 | $24K |
| 87799 | <1% | 3,234 | $23K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,298 | $22K |
| 86834 | <1% | 365 | $22K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 126 | $22K |
| 73130 | <1% | 1,267 | $21K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 614 | $21K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,702 | $21K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,236 | $20K |
| 43235 | <1% | 44 | $20K | |
| 70486 | <1% | 271 | $19K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 166 | $18K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 87 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,653 | $18K |
| 73110 | <1% | 1,017 | $16K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 32 | $15K |
| 20550 | <1% | 61 | $14K | |
| 80076 | <1% | 7,305 | $14K | |
| 70491 | <1% | 93 | $14K | |
| 96402 | <1% | 350 | $13K | |
| 83735 | <1% | 13,921 | $12K | |
| C1769 | Guide wire | <1% | 1,946 | $12K |
| 93017 | <1% | 129 | $11K | |
| 82248 | <1% | 2,916 | $11K | |
| 88341 | <1% | 376 | $11K | |
| 80047 | <1% | 1,649 | $11K | |
| 83880 | <1% | 2,345 | $10K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 172 | $10K |
| 86850 | <1% | 4,589 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 31 | $9K |
| 73560 | <1% | 131 | $9K | |
| 85610 | <1% | 9,701 | $9K | |
| 86923 | <1% | 131 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 43 | $8K |
| 86900 | <1% | 5,150 | $8K | |
| 95886 | <1% | 47 | $8K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 249 | $8K |
| 96376 | <1% | 4,048 | $8K | |
| 95811 | <1% | 27 | $8K | |
| 84484 | <1% | 8,245 | $7K | |
| 86835 | <1% | 366 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 20,585 | $7K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 36 | $7K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,261 | $6K |
| 84100 | <1% | 9,939 | $5K | |
| 82728 | <1% | 1,884 | $5K | |
| 77065 | Tomosynthesis, mammo | <1% | 111 | $5K |
| 81001 | <1% | 14,983 | $5K | |
| 97035 | <1% | 44 | $5K | |
| 90715 | <1% | 186 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 557 | $4K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 162 | $4K |
| 87581 | <1% | 871 | $4K | |
| 82962 | <1% | 12,121 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,825 | $4K |
| 88307 | <1% | 172 | $4K | |
| 85379 | <1% | 1,142 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,856 | $4K |
| 86828 | <1% | 364 | $4K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,521 | $3K |
| 96523 | <1% | 88 | $3K | |
| 73590 | <1% | 306 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,553 | $3K |
| 86901 | <1% | 5,149 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 412 | $3K |
| 87040 | <1% | 519 | $3K | |
| 97166 | <1% | 17 | $3K | |
| 73620 | <1% | 226 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 959 | $3K |
| 95913 | <1% | 28 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,715 | $3K |
| 83605 | <1% | 2,865 | $3K | |
| 88342 | <1% | 938 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,300 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 528 | $3K |
| 72110 | <1% | 63 | $3K | |
| 83690 | <1% | 7,275 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $2K |
| 82570 | <1% | 4,145 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 27 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 188 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 528 | $2K |
| 87486 | <1% | 624 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,129 | $2K |
| 83615 | <1% | 2,754 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,340 | $2K |
| 84702 | <1% | 1,904 | $2K | |
| 73140 | <1% | 152 | $2K | |
| 87070 | <1% | 1,862 | $2K | |
| 83970 | <1% | 472 | $2K | |
| 85027 | <1% | 1,120 | $2K | |
| C9399 | Unclassified drugs or biologicals | <1% | 1,780 | $2K |
| C1776 | Joint device (implantable) | <1% | 13 | $2K |
| 82977 | <1% | 365 | $2K | |
| 83550 | <1% | 1,264 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,944 | $1K |
| 77073 | <1% | 45 | $1K | |
| 70498 | <1% | 31 | $1K | |
| 77061 | <1% | 15 | $1K | |
| 83540 | <1% | 1,357 | $1K | |
| 83520 | <1% | 205 | $1K | |
| 76937 | <1% | 36 | $1K | |
| 88304 | <1% | 196 | $1K | |
| 74018 | <1% | 79 | $1K | |
| 76801 | <1% | 182 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 8,431 | $1K |
| 82607 | <1% | 1,300 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 682 | $1K |
| 84156 | <1% | 3,396 | $1K | |
| 88185 | <1% | 48 | $1K | |
| 85730 | <1% | 2,449 | $1K | |
| 84439 | <1% | 1,199 | $906.30 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,710 | $891.54 |
| 90686 | <1% | 101 | $857.95 | |
| 87077 | <1% | 1,570 | $835.96 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,240 | $811.77 |
| 87340 | <1% | 541 | $788.65 | |
| 82803 | <1% | 2,422 | $781.02 | |
| 82784 | <1% | 521 | $779.84 | |
| 73080 | <1% | 29 | $777.38 | |
| 80061 | Lipid panel | <1% | 1,044 | $752.20 |
| 86140 | <1% | 1,873 | $751.81 | |
| C1758 | Catheter, ureteral | <1% | 61 | $750.06 |
| 80320 | <1% | 639 | $721.67 | |
| 81025 | <1% | 3,584 | $709.59 | |
| 87522 | Neg quan hep c or qual rna | <1% | 145 | $698.40 |
| 86592 | <1% | 602 | $688.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 583 | $593.84 |
| 84550 | <1% | 2,356 | $574.68 | |
| 85045 | <1% | 765 | $526.53 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,499 | $524.34 |
| 96417 | <1% | 1,202 | $476.95 | |
| Q3014 | Telehealth originating site facility fee | <1% | 66 | $458.96 |
| 88360 | <1% | 14 | $444.82 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 214 | $444.67 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,898 | $406.51 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 420 | $392.03 |
| 82105 | <1% | 93 | $383.62 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 887 | $364.83 |
| 88184 | <1% | 32 | $340.42 | |
| 85014 | <1% | 2,717 | $338.89 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,011 | $326.21 |
| 77300 | <1% | 21 | $326.09 | |
| 76000 | <1% | 41 | $317.00 | |
| 84703 | <1% | 1,511 | $293.95 | |
| 82150 | <1% | 191 | $269.78 | |
| 82378 | <1% | 314 | $255.26 | |
| 87075 | <1% | 382 | $237.90 | |
| 83883 | <1% | 65 | $234.41 | |
| 87186 | <1% | 1,491 | $233.51 | |
| 82550 | <1% | 737 | $232.74 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,707 | $230.74 |
| 82746 | <1% | 579 | $228.35 | |
| 86334 | <1% | 79 | $186.12 | |
| 87205 | <1% | 879 | $184.33 | |
| 73552 | <1% | 12 | $177.40 | |
| 87428 | <1% | 209 | $159.00 | |
| 88142 | <1% | 19 | $151.02 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 361 | $147.72 |
| 84165 | <1% | 303 | $145.71 | |
| 85652 | <1% | 785 | $141.71 | |
| 81003 | <1% | 1,192 | $135.60 | |
| 82330 | <1% | 512 | $125.51 | |
| 82077 | <1% | 1,050 | $108.90 | |
| 82043 | <1% | 611 | $95.69 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,076 | $92.85 |
| 85651 | <1% | 640 | $89.83 | |
| 86481 | <1% | 14 | $87.90 | |
| J3490 | Unclassified drugs | <1% | 4,868 | $86.80 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 84 | $83.66 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 286 | $70.77 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 84 | $55.70 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,905 | $53.57 |
| 81002 | <1% | 486 | $52.46 | |
| 86704 | <1% | 37 | $49.16 | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 12 | $44.62 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,977 | $43.46 |
| G0008 | Administration of influenza virus vaccine | <1% | 104 | $42.40 |
| 86317 | <1% | 36 | $39.98 | |
| 82565 | <1% | 213 | $39.77 | |
| 99220 | <1% | 14 | $33.18 | |
| 84153 | <1% | 42 | $31.27 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,712 | $31.02 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,278 | $28.89 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 633 | $25.47 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 611 | $24.95 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,763 | $24.55 |
| 82947 | <1% | 386 | $20.58 | |
| 82375 | <1% | 449 | $16.70 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,011 | $15.46 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 233 | $11.19 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 690 | $9.68 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 502 | $8.74 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 423 | $7.76 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 348 | $5.98 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,165 | $5.81 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,072 | $4.87 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 641 | $4.56 |
| 84295 | <1% | 353 | $3.50 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 99 | $2.01 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 95 | $0.90 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 399 | $0.87 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 63 | $0.52 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 15 | $0.26 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 16 | $0.26 |
| 84403 | 0% | 24 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 380 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 21 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 434 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 155 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 236 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 244 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 25 | $0.00 |
| 0272 | 0% | 178 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 30 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 63 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 39 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 26 | $0.00 |
| 88313 | 0% | 15 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 215 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 80 | $0.00 |
| 0370 | 0% | 121 | $0.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 32 | $0.00 |
| 0710 | 0% | 134 | $0.00 | |
| 0250 | 0% | 594 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 41 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 43 | $0.00 |
| 94760 | 0% | 17 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 32 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 13 | $0.00 |
| 84132 | 0% | 29 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 30 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 48 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 79 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHO, DAVID (VP OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Modern Family Medicine Main Line LLC | Bryn Mawr, PA | $99K |
| David S Ho MD PA | Houston, TX | $35K |
| Lexington Optical Express | New York, NY | $9K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.